AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 157 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 1.22 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $43,456,000 | -26.8% | 760,116 | -14.5% | 0.65% | -26.1% |
| Q3 2017 | $59,350,000 | +50.0% | 889,142 | +15.6% | 0.88% | +55.4% |
| Q2 2017 | $39,562,000 | +11.0% | 768,942 | +26.0% | 0.56% | +13.0% |
| Q1 2017 | $35,629,000 | +34.2% | 610,086 | -4.1% | 0.50% | +34.0% |
| Q4 2016 | $26,552,000 | -19.7% | 636,290 | +1.7% | 0.37% | -13.9% |
| Q3 2016 | $33,046,000 | +97.6% | 625,627 | +56.7% | 0.43% | +123.2% |
| Q2 2016 | $16,726,000 | -3.5% | 399,236 | -6.5% | 0.19% | +3.7% |
| Q1 2016 | $17,335,000 | -38.9% | 426,960 | -2.3% | 0.19% | -34.2% |
| Q4 2015 | $28,370,000 | +2.5% | 436,994 | +11.4% | 0.28% | +28.5% |
| Q3 2015 | $27,681,000 | -47.7% | 392,133 | -17.7% | 0.22% | -35.2% |
| Q2 2015 | $52,970,000 | +62.8% | 476,604 | +38.1% | 0.34% | +92.7% |
| Q1 2015 | $32,534,000 | – | 345,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |